search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Assessment of sympathetic reinnervation of the kidney allograft with 123I-MIBG scintigraphy


- candidate number14909
- NTR NumberNTR4005
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR21-mei-2013
- Secondary IDsNL42557.018.13 METC AMC
- Public TitleAssessment of sympathetic reinnervation of the kidney allograft with 123I-MIBG scintigraphy
- Scientific TitleAssessment of sympathetic reinnervation of the kidney allograft with 123I-MIBG scintigraphy
- ACRONYMRENnervate study
- hypothesisWe hypothesize that allograft sympathetic reinnervation is a slow process which takes >10 years to reach functional capacity and thatt 123I-MIBG scintigraphy can assess functional reinnervation of the kidney allograft.
- Healt Condition(s) or Problem(s) studiedRenal transplant , Innervation, 123I-MIBG
- Inclusion criteriaRecently transplanted patients (n=6)
- Renal graft in situ for 6-18 months at time of measurement or Approximately 5 year renal transplant survivors (n=6);
-Renal graft in situ for > 4 < 7 years at time of measurement

Long term graft survivors (n=6):
- Renal graft in situ for >10 years at time of measurement

All patients have:
- A measured creatinine clearance 50 ml/min;
- At least one native kidney in situ.
- Exclusion criteria- Pregnancy;
- Unable to give informed consent;
- Absolute indication for alpha and/or beta-blocking agents.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeintervention
- planned startdate 15-mei-2013
- planned closingdate1-jun-2014
- Target number of participants18
- InterventionsAll patients will undergo 123I-MIBG scintigraphy. They will receive 185 MBq of 123I-MIBG intravenously. Subsequently at 15 min and 4 hrs and 24 hours post injection planar images are made in combination with SPECT at 4 and 24 hours post injection. The SPECT acquisition is combined with a low dose CT-scan of the abdomen (without intravenous contrast) to relate the 123I-MIBG uptake to anatomical structures.
- Primary outcomeTo compare allograft sympathetic reinnervation by 123I-MIBG washout rates between patients with a recent transplantation (6-18 months), patients with an allograft in situ for > 4 and <7 years and patients who have a kidney transplantant >10 years.
- Secondary outcomeN/A
- TimepointsPrimary data are based on one 123I-MIBG scintigraphy.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDr. MD. PhD. C.T.P. Krediet
- CONTACT for SCIENTIFIC QUERIESDr. MD. PhD. C.T.P. Krediet
- Sponsor/Initiator Academic Medical Center (AMC, Amsterdam)
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC)
- PublicationsN/A
- Brief summaryA number of renal transplant recipients have excellent functioning grafts for many years after transplantation. Most obvious this is due to immunological factors, infection rates and comorbidity. However, it is unclear whether renal nerve regrowth in the allograft might influence graft survival. Due to the explantation process, the renal allograft is entirely denervated at time of transplantation. In years after transplantation, it is unknown to what extend and when regeneration of renal sympathetic nerves after transplantation occurs. Assessment of the sympathetic nerve activity (SNA) can be determined by peroneus microneurography or catecholamine levels in plasma. However, these methods are indirect, invasive and impractical and do not supply information about regional sympathetic nerve activity. 123I-metaiodobenzylguanidine (123I-MIBG) is a radio-labeled analogue of noradrenaline and is taken up by presynaptic nor-adrenaline transporters and thereby it can provide an estimate of sympathetic activity. 123I-MIBG scintigraphy has shown to offer prognostic information in patients with heart failure. Since kidney transplantation is the only durable therapy for end stage renal disease, allograft nephropathy remains an important clinical problem. Various lines of evidence suggest that sympathetic denervation of the allograft plays a role in the pathogenesis of allograft nephropathy. Due to the explantation process, the renal allograft is entirely denervated at time of transplantation. There is histological evidence that after transplantation there is re-innervation of the allograft. However, up to 2,5 years after transplantation such reinnervation has been shown not to be of functional significance. Reinnervation is a potential therapeutic aim to prevent allograft nephropathy. We hypothesize that allograft sympathetic reinnervation is a slow process which takes >10 years to reach functional capacity. If there is a >7.5% difference in washout-rate n the kidney graft compared to the mediastinum, we assume that this implicates reinnervation of the graft. We assume that if renal re-innervation occurs, 123I-MIBG uptake will be higher in patients with an older renal allograft compared to recent transplanted allografts that show decreased or lack of 123I-MIBG uptake.Therefore, patients with a graft in situ for > 10 years will be studied initially.
- Main changes (audit trail)
- RECORD21-mei-2013 - 29-mei-2013


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl